Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

Healthcare is drawing fresh buying as money moves away from the market’s popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA ...

Pfizer and BioNTech have paused a large U.S. clinical trial designed to test their updated COVID-19 vaccine in healthy adults aged 50 through 64, citing an inability to recruit enough participants.

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, ...

European regulators have officially approved the latest 2026–2027 COVID-19 vaccine formula from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). Designed to protect against the widespread XFG ...

BioNTech's oncology pipeline could help it make a dent in this large and growing market. However, there is one thing investors should consider before initiating a position. 10 stocks we like better ...

Pfizer has put the kibosh on two early-stage programs from its $43 billion Seagen buyout. (iStock / Getty Images Plus) Pfizer has axed 11 programs including two pipeline assets from its $43 billion ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BioNTech (BNTX) ADRs lost ~5% in the premarket on Thursday after Bloomberg News reported that Pfizer (PFE) is planning to sell its remaining stake in its partner, which helped the U.S. pharma giant to ...